Landmark Bio Breaks Ground

A Boston-area collaboration on advanced life-sciences techniques

Ran Zheng

Ran Zheng | Photograph courtesy Kris Snibbe/Harvard University

Construction began today on a state-of-the-art biomanufacturing facility in a 40,000-square-foot leased space at the Watertown Arsenal, a few miles west of Harvard Square, culminating a several-year process of developing a Boston-area research collaborative. Ran Zheng, a veteran of the biotechnology industry, has been appointed CEO of the company, which will help develop emerging cell- and gene-based therapies for human use. Founded and led by Harvard, MIT, Cytiva (formerly part of GE Healthcare Life Sciences), FUJIFILM Diosynth Biotechnologies, and Alexandria Real Estate (a developer of labs and offices), the company was recently renamed Landmark Bio (formerly, the Center for Advanced Biological Innovation and Manufacturing). Five Harvard-affiliated hospitals—Brigham and Women’s, Massachusetts General Hospital, the Dana-Farber Cancer Institute, Boston Children’s, and Beth Israel Deaconess Medical Center—are collaborating institutions, together with the Massachusetts Life Sciences Center. (MilliporeSigma, a provider of industrial and lab chemicals, is apparently no longer formally involved.)

Zheng, a chemical engineer by training, has extensive experience in biotechnology process development, including Good Manufacturing Practices (GMP), a U.S. Food and Drug Administration certification necessary for most human therapies that is recognized by pharmaceutical companies and regulatory agencies worldwide. In addition to GMP manufacturing capacity (including the ability to create mRNA therapies delivered in lipid nanoparticles—an approach made famous by the Moderna and Pfizer coronavirus vaccines), the facility will include innovation and process development laboratories that will help researchers from academic, healthcare, and industry partners turn their research discoveries and laboratory protocols into products for human use. Warehouse space will be used to store patient and healthy donor materials, as well as therapeutic products destined for clinical testing.

Harvard provost Alan M. Garber, who chairs the board of Landmark Bio and has led the multi-institution collaboration that created it (see “Accelerating Cell Manufacture”), said in a statement that Zheng is “a leader with broad and deep industry expertise and an impressive record of achievement in technology development and global clinical development….The kickoff today on the construction of Landmark Bio’s state-of-the-art facility is just the first step in our collective efforts to innovate in biological manufacturing”—part of Harvard’s efforts to strengthen what is perceived as one of the nation’s leading biomedical and biotechnology research centers. 

Although biological therapies are harder to develop than chemical therapies, they are approximately twice as likely to receive regulatory approval as typical small-molecule drugs (which are taken orally, in pill form).

Updated 8-17-2021 to reflect that Cytiva was just a part of GE Healthcare Life Sciences, not the entire enterprise.

Read more articles by Jonathan Shaw
Related topics

You might also like

Five from Harvard Named Rhodes Scholars

Four Americans and one Canadian will begin studies at Oxford next fall.

Judge Vacates Trump Administration Limit on International Student Visas

Harvard was in a group of plaintiffs that filed suit against the rule in August.

Harvard Academic Workers Begin Strike

A second union joined graduate students on the picket line, emptying labs and classrooms.

Most popular

These Harvard Graduates Are Candidates for Sainthood

For advocacy and benevolence, three late alumni are reportedly in line for the Catholic Church’s highest honor.

How Philosophy at Harvard Saved Itself

As humanities shrink across higher education, one department is flourishing. Is its success a fluke, or a roadmap?

Harvard Weathers a Year of Turmoil

The federal government has launched unprecedented actions against the University. Here’s a guide.

Explore More From Current Issue

Panoramic view of Harvard University with autumn foliage and a river under a cloudy sky.

The University is expanding industry ties and investing its own funds to support research, but neither will replace lost federal dollars.

Ancient Egyptian painted sarcophagus with detailed hieroglyphs and a woman's face.

A rare Egyptian mummy case is on display at the Harvard Museum of the Ancient Near East.

Illustration of a phone, book, hourglass, weights, and a hand reaching for a device on a blue background.

Your thoughts on how to regulate the platforms—and stop using them so much